Everyone loves the idea of personalised healthcare, but when it’s been trialled in the past, the cost is often too high, both for the pharmaceutical companies producing the drugs and for the patients and healthcare systems.
“That's why the pharma companies like to develop ‘blockbusters’. It's just one drug for all,” Dr Alex Ng told Euronews Health.
